For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 0 | |||
| Research and development | 34,352,332 | |||
| General and administrative | 14,601,031 | |||
| Total operating expenses | 48,953,363 | |||
| Loss from operations | -48,953,363 | |||
| Changes in fair value of warrant liabilities | -62,754,186 | |||
| Interest expense | 240,664 | |||
| Interest income | 1,432,032 | |||
| Other income | 3,133,784 | |||
| Warrant issuance expense | 4,852,292 | |||
| Total other income | 62,227,046 | |||
| Net income (loss) | 13,273,683 | |||
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | 185,464 | |||
| Foreign currency translation gain (loss) | 136,456 | |||
| Total comprehensive income (loss) | 13,595,603 | |||
| Basic EPS | 0.22 | |||
| Diluted EPS | -0.79 | |||
| Basic Average Shares | 19,311,798 | |||
| Diluted Average Shares | 61,340,193 | |||
SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc. (SABSW)